Periodontal Microbiota in Systemic Sclerosis

NCT ID: NCT06182293

Last Updated: 2025-08-06

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-10-24
• Study Completion Date: 2025-10-24

Brief Summary

Systemic sclerosis (SSc) is a rare and complex autoimmune disease. Although its etiology remains unknown, various environmental factors, including certain microorganisms, can represent potential triggers of SSc in individuals with a permissive genetic background. Patients show a wide spectrum of clinical features including periodontitis, which is an inflammatory disease of the tooth-supporting tissues resulting from dysbiosis of the periodontal microbiota guided by inflammophilic bacteria.

The microbiota plays a fundamental role in the induction, training, and function of the host immune system. Numerous studies have highlighted the impact of an altered microbiota, i.e. dysbiosis, on the pathogenesis of immune-mediated diseases. Indeed, commensals are important to maintain immune homeostasis and changes in the microbial composition can be responsible for a loss of tolerance. SSc has been shown to be associated with gut dysbiosis and a depletion of commensals. However, although the oral cavity is one of the two largest microbial habitats, only one study (only focusing on Lactobacillus species) has investigated the oral microbiota in SSc. As periodontal dysbiosis is known to induce low-grade systemic inflammation and represents a risk factor for the development of various autoimmune diseases, the relationship between periodontal microbiota composition and SSc merits further exploration.

The aim of this pilot study is to characterize the taxonomic composition and metabolic pathways of the periodontal microbiota in SSc patients and age and sex-matched controls.

Conditions

Scleroderma Systemic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Systemic sclerosis

Group Type: OTHER

Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota

Intervention Type: OTHER

Subgingival plaque will be collected at 6 sites using sterile curettes after removal of supragingival biofilm by brushing. After microbial DNA extraction, whole metagenome will be sequenced.

Controls

Group Type: OTHER

Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota

Intervention Type: OTHER

Subgingival plaque will be collected at 6 sites using sterile curettes after removal of supragingival biofilm by brushing. After microbial DNA extraction, whole metagenome will be sequenced.

Interventions

Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota

Subgingival plaque will be collected at 6 sites using sterile curettes after removal of supragingival biofilm by brushing. After microbial DNA extraction, whole metagenome will be sequenced.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Men or women over 18 (adults)
• Affiliation to a social health insurance plan
• Subject able to understand the aims and risks of the research and to give signed informed consent form prior to the inclusion in the study
• More than 12 teeth suitable for evaluation

• Systemic sclerosis patient with a diagnosis based on the American College of Rheumatology/European League Against Rheumatism criteria (LeRoy et al., 1988 ; van den Hoogen et al., 2013)
• Diagnosis made during the 2 years preceding study inclusion (early form of the disease)

• Patient attending the Oral Medicine and Surgery Department from the University Hospital of Strasbourg for a routine dental consultation

Exclusion Criteria

• - Subject under court protection
• Subject under guardianship or curatorship
• Pregnancy or breastfeeding
• Impossibility to provide accurate information (emergency situation, comprehension difficulties…)
• Subject currently involved in another clinical trial or in an exclusion period following participation in another clinical trial
• Smoking (≥ 10 cigarettes per day)
• Other associated systemic auto-immune disease (Sjögren syndrome with positive serum anti-SSA and/or anti-SSB auto-antibodies, systemic lupus erythematosus…)
• Progressive chronic illness other than systemic sclerosis
• Acute infection at inclusion
• Progressive cancer or cancer diagnosed within 2 years prior to the study
• Ongoing antibiotic and/or antifungal treatment or within 3 months prior to inclusion
• Probiotics and/or prebiotics intake within 3 months prior to inclusion
• Oral antiseptics within the week before inclusion (chlorhexidin mouthwashes…)
• Risk of infective endocarditis
• Corticosteroids ≥10 mg/day and/or proton pump inhibitors within 3 months prior to inclusion
• Previous hematopoietic stem cell transplantation
• Another cause of skin sclerosis (radiotherapy of the orofacial area…)
• Periodontal specialized treatments, root and/or periodontal surgical treatment and/or subgingival instrumentation within the year before inclusion

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Strasbourg, France

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Clinique Dentaire

Strasbourg, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Sophie JUNG, MD

Role: CONTACT

sophie.jung1@chru-strasbourg.fr

03.88.11.69.10

Facility Contacts

Sophie JUNG, MD

Role: primary

Other Identifiers

9149

Identifier Type: -

Identifier Source: org_study_id